Monday, November 11, 2019
- 9:00AM-11:00AM
-
Abstract Number: 1272
Biological Therapy in Non Ischaemic Optic Neuritis Associated to Immune-mediated Inflammatory Diseases: Multicenter Study
Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies- 9:00AM-11:00AM
-
Abstract Number: 1080
Biosimilar Etanercept Use in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: The RHUMADATA® Registry Experience
Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease- 9:00AM-11:00AM
-
Abstract Number: 1490
Blockage of TNFα and IL-12/23 Improves Depressive Symptoms in Patients with Psoriatic Arthritis – Analysis of Clinical Trial Data
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1627
Bronchoalveolar Lavage Fluid Analysis and Mortality Risk in Systemic Lupus Erythematosus Patients with Pneumonia and Respiratory Failure
SLE – Clinical Poster II: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 974
Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Disease: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 967
Bruton’s Tyrosine Kinase (BTK) Pathway Is Active in Synovium at Various Stages of Rheumatoid Arthritis Disease Progression
B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 1008
C-X-C Motif Chemokine 10 (CXCL10) as a Transcriptomic Biomarker of Psoriatic Arthritis Susceptibility
Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster- 9:00AM-11:00AM
-
Abstract Number: 1567
Cachexia in Systemic Lupus Erythematosus
SLE – Clinical Poster II: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 1194
Can an MDHAQ (Multidimensional Health Assessment Questionnaire) 60-Symptom Checklist to Monitor Early Medication Outcomes (MDHAQ/MEMO60) Detect Adverse Events of High-Risk Medications?
Measures Of Healthcare Quality Poster II: Improving Care- 9:00AM-11:00AM
-
Abstract Number: 1250
Can Patient-Reported Outcomes and Disease Activity Scores Predict Patient Acceptable Symptom State in Adult-Onset Still’s Disease?
Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies- 9:00AM-11:00AM
-
Abstract Number: 1570
Can the Montreal Cognitive Assessment (MoCA) Improve the Automated Neuropsychological Assessment Metrics (ANAM) Performance in Screening for Cognitive Impairment in Lupus Patients?
SLE – Clinical Poster II: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 1714
Can We Predict Early Relapses in Adult IgA Vasculitis?
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides- 9:00AM-11:00AM
-
Abstract Number: 1082
Cancer Risk in Patients with Ankylosing Spondylitis: A Nationwide Population-based Dynamic Cohort Study from Korea